More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

The studies further strengthen HeartBeam’s body of clinical evidence for its portable, cable-free, credit card-sized device that is designed to be capable of synthesizing a 12-lead ECG ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

New research suggests that a procedure now regarded as Plan B when patients have episodes of rapid heartbeat after a ...

Japanese researchers say they have found a pill that works as well as existing medication to prevent blood clots afte ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular ...

The combination of sacubitril and valsartan reduces the cardiotoxicity related to anthracycline chemotherapy drugs, according ...

An experimental oral drug called muvalaplin shows promise in reducing the cholesterol linked to heart disease in a study.

Inflammation is generally the indication of a health problem. But new research suggests we think differently about inflammation, especially in relation to heart disease and the prevention of atheroscl ...